JP2017000143A5 - - Google Patents

Download PDF

Info

Publication number
JP2017000143A5
JP2017000143A5 JP2016130526A JP2016130526A JP2017000143A5 JP 2017000143 A5 JP2017000143 A5 JP 2017000143A5 JP 2016130526 A JP2016130526 A JP 2016130526A JP 2016130526 A JP2016130526 A JP 2016130526A JP 2017000143 A5 JP2017000143 A5 JP 2017000143A5
Authority
JP
Japan
Prior art keywords
growth factor
fusion protein
tissue
cell
activation domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016130526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017000143A (ja
JP6174763B2 (ja
Filing date
Publication date
Priority claimed from US13/068,808 external-priority patent/US9238080B2/en
Application filed filed Critical
Publication of JP2017000143A publication Critical patent/JP2017000143A/ja
Publication of JP2017000143A5 publication Critical patent/JP2017000143A5/ja
Application granted granted Critical
Publication of JP6174763B2 publication Critical patent/JP6174763B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016130526A 2010-05-21 2016-06-30 二重特異的融合タンパク質 Active JP6174763B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34704010P 2010-05-21 2010-05-21
US61/347,040 2010-05-21
US13/112,907 2011-05-20
US13/068,808 2011-05-20
US13/068,808 US9238080B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins
US13/112,907 US8691771B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins for tissue repair

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013511403A Division JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017132859A Division JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質

Publications (3)

Publication Number Publication Date
JP2017000143A JP2017000143A (ja) 2017-01-05
JP2017000143A5 true JP2017000143A5 (cg-RX-API-DMAC7.html) 2017-06-22
JP6174763B2 JP6174763B2 (ja) 2017-08-02

Family

ID=44972647

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013511403A Active JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質
JP2016130526A Active JP6174763B2 (ja) 2010-05-21 2016-06-30 二重特異的融合タンパク質
JP2017132859A Active JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質
JP2019117073A Active JP6965311B2 (ja) 2010-05-21 2019-06-25 二重特異的融合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013511403A Active JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017132859A Active JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質
JP2019117073A Active JP6965311B2 (ja) 2010-05-21 2019-06-25 二重特異的融合タンパク質

Country Status (9)

Country Link
US (11) US8691771B2 (cg-RX-API-DMAC7.html)
EP (1) EP2571992B1 (cg-RX-API-DMAC7.html)
JP (4) JP6200806B2 (cg-RX-API-DMAC7.html)
CN (1) CN103124788B (cg-RX-API-DMAC7.html)
AU (1) AU2011255238B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012029611A2 (cg-RX-API-DMAC7.html)
CA (1) CA2800173C (cg-RX-API-DMAC7.html)
ES (1) ES2674567T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011146902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110112301A (ko) * 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
ES2674567T3 (es) * 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN103987401A (zh) * 2011-04-28 2014-08-13 范斯坦医药研究院 Mfg-e8及其用途
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
WO2014139468A1 (en) * 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) * 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3283068A1 (en) 2015-04-17 2018-02-21 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
CN104946656B (zh) * 2015-06-08 2018-08-17 吉林省农业科学院 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
US20190002516A1 (en) * 2015-12-21 2019-01-03 Hefei Lifeon Pharmaceutical Co., Ltd. Drug Design Method, Obtained Drug and Application Thereof
CA3009799A1 (en) * 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
UY37105A (es) 2016-02-03 2017-09-29 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
CA3011949A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
NZ749292A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
AU2018298060B2 (en) 2017-07-03 2021-02-25 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
EP3658186A4 (en) * 2017-07-24 2020-08-12 Rutgers, The State University of New Jersey FUSION MOLECULES TARGETING PHOSPHATIDYLSERINE AND THEIR METHODS OF USE
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
US11464803B2 (en) * 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
GB201919019D0 (en) * 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
EP4103612A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9
US20230096030A1 (en) * 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
JP2023537318A (ja) * 2020-07-30 2023-08-31 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド 中枢神経系障害の処置のためのキメラタンパク質および使用方法
CN115286713B (zh) * 2020-10-27 2024-07-23 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
WO2022092974A1 (ko) * 2020-10-30 2022-05-05 (주)셀레메디 항체 유사 단백질 및 그 용도
US11946055B2 (en) * 2020-12-10 2024-04-02 The Regents Of The University Of California Protein engineering via error-prone orthogonal replication and yeast surface display
WO2022235061A1 (ko) * 2021-05-03 2022-11-10 (주)셀레메디 신규 단백질
CN117659178B (zh) * 2022-08-23 2024-09-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体或其功能性片段、检测甲型流感病毒的试剂和试剂盒
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
CN118420712A (zh) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 一种三特异性抗体技术平台及其应用
CN116983407B (zh) * 2023-08-03 2025-10-28 艾可泰科(浙江)控股有限公司 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺
CN117736344B (zh) * 2024-01-30 2024-06-21 南通大学 具有自组装性能的重复结构单元重组蛋白ⅡAⅡB-ⅡAⅡBrQTY及应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
AU7042994A (en) * 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
AU2601895A (en) 1994-05-24 1995-12-18 Amgen Boulder Inc. Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
AU2676297A (en) 1996-04-17 1997-11-07 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ES2188202T3 (es) * 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
PT1141015E (pt) 1999-01-06 2009-10-13 Genentech Inc Variantes mutantes do factor de crescimento do tipo insulina (igf)i
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DE60025830T2 (de) 1999-07-21 2006-11-02 University Of Southern California, Los Angeles Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
EP1313499B1 (en) 2000-08-29 2010-04-07 Aurogen Incorporated Method for treating the central nervous system by administration of igf structural analogs
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
DE60224816T2 (de) 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
AU2003241313A1 (en) 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2003103577A2 (en) 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
WO2004100961A1 (ja) 2003-05-19 2004-11-25 Seikagaku Corporation 硫酸基転移酵素阻害剤
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
RU2356909C2 (ru) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
US20060018897A1 (en) 2004-06-28 2006-01-26 Transtarget Inc. Bispecific antibodies
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
EP1784204A4 (en) 2004-08-20 2008-11-05 Univ Texas PROCESS FOR PREPARING, PREVENTING, INHIBITING OR REDUCING DAMAGE TO HEART TISSUE
CA2582552A1 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
PL2289535T3 (pl) * 2004-12-21 2018-12-31 Musc Foundation For Research Development Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek
ATE517120T1 (de) 2005-01-07 2011-08-15 Regeneron Pharma Igf-1 fusion polypeptide und deren therapeutische verwendung
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
NZ556065A (en) * 2005-01-24 2009-04-30 Univ Texas FC-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
JP2008545715A (ja) * 2005-05-27 2008-12-18 ファイブ プライム セラピューティクス， インコーポレイテッド 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物
BRPI0614761A2 (pt) * 2005-08-12 2009-05-19 Human Genome Sciences Inc proteìnas de fusão de albumina
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
ES2617002T3 (es) 2005-12-12 2017-06-15 Mosamedix B.V. Derivados de anexina adecuados para la prefocalización en terapia y diagnóstico
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
MX2008010561A (es) 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
SE530073C2 (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
WO2008151005A2 (en) 2007-05-31 2008-12-11 Transtarget, Inc. Compositions and methods for tissue repair
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
JP2012516330A (ja) 2009-01-31 2012-07-19 アイジーエフ オンコロジー エルエルシー 抗癌タンパク質−白金コンジュゲート
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US8759299B2 (en) 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
ES2674567T3 (es) * 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
CN103354835B (zh) 2010-12-08 2016-03-02 韦尔赛特公司 抑制人多能干细胞生长的试剂和方法
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013086785A1 (zh) 2011-12-15 2013-06-20 Qin Shulin 具有降血糖作用的化合物、组合物及其用途
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
MX2015013803A (es) 2013-03-29 2016-02-16 Merrimack Pharmaceuticals Inc Proteina de fusion de enlace al cartilago.
CA2936675C (en) 2014-01-12 2023-06-27 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
EP3355907B1 (en) * 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
US11290711B2 (en) 2018-10-06 2022-03-29 Mediatek Inc. Method and apparatus of shared merge candidate list region for video coding

Similar Documents

Publication Publication Date Title
JP2017000143A5 (cg-RX-API-DMAC7.html)
JP2013530146A5 (cg-RX-API-DMAC7.html)
JP2019196365A5 (cg-RX-API-DMAC7.html)
Ren et al. Osteogenesis on nanoparticulate mineralized collagen scaffolds via autogenous activation of the canonical BMP receptor signaling pathway
MY179505A (en) Recombinant binding proteins and their use
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
Assal et al. The promotion of angiogenesis by growth factors integrated with ECM proteins through coiled-coil structures
MY204384A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
Kaneko et al. A 3D nanofibrous hydrogel and collagen sponge scaffold promotes locomotor functional recovery, spinal repair, and neuronal regeneration after complete transection of the spinal cord in adult rats
EA200802289A1 (ru) Направляемые к мишени антителами цитокины для терапии
SG178930A1 (en) Therapeutic dll4 binding proteins
WO2013184960A3 (en) Chimeric fibroblast growth factor 23 proteins and methods of use
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
Sufen et al. bFGF and PDGF‐BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells
EP3321276A3 (en) Fusion proteins for treating metabolic disorders
MX2017013520A (es) Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
JP2016521688A5 (cg-RX-API-DMAC7.html)
TN2019000119A1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
WO2018081726A3 (en) Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
AR073078A1 (es) Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.
WO2019014360A8 (en) POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF
Lowery et al. A survey of strategies to modulate the bone morphogenetic protein signaling pathway: current and future perspectives